These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39116084)

  • 1. Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study.
    Karacabeyli D; Lacaille D; Lu N; McCormick N; Xie H; Choi HK; Aviña-Zubieta JA
    PLoS One; 2024; 19(8):e0308533. PubMed ID: 39116084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study.
    Zareini B; Sørensen KK; Pedersen-Bjergaard U; Loldrup Fosbøl E; Køber L; Torp-Pedersen C
    J Diabetes; 2024 Jun; 16(6):e13560. PubMed ID: 38751369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice.
    Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2020 Jun; 19(1):74. PubMed ID: 32522260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
    Xu L; Zheng XQ; Liao XX
    Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.
    Tan X; Liang Y; Rajpura JR; Yedigarova L; Noone J; Xie L; Inzucchi S; de Havenon A
    Cardiovasc Diabetol; 2023 Nov; 22(1):319. PubMed ID: 37985992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.
    Barkmeier AJ; Herrin J; Swarna KS; Deng Y; Polley EC; Umpierrez GE; Galindo RJ; Ross JS; Mickelson MM; McCoy RG
    Ophthalmol Retina; 2024 Oct; 8(10):943-952. PubMed ID: 38735641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
    Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
    Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
    JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.
    Huang T; Bosi A; Faucon AL; Grams ME; Sjölander A; Fu EL; Xu Y; Carrero JJ
    JAMA Intern Med; 2024 Oct; 184(10):1195-1203. PubMed ID: 39133509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagonlike peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in ischemic strokes with diabetes 2.
    Hastrup S; Hedegaard JN; Andersen G; Rungby J; Johnsen SP
    Eur J Neurol; 2024 Aug; 31(8):e16329. PubMed ID: 38715389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
    Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
    PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.
    Khera R; Aminorroaya A; Dhingra LS; Thangaraj PM; Pedroso Camargos A; Bu F; Ding X; Nishimura A; Anand TV; Arshad F; Blacketer C; Chai Y; Chattopadhyay S; Cook M; Dorr DA; Duarte-Salles T; DuVall SL; Falconer T; French TE; Hanchrow EE; Kaur G; Lau WCY; Li J; Li K; Liu Y; Lu Y; Man KKC; Matheny ME; Mathioudakis N; McLeggon JA; McLemore MF; Minty E; Morales DR; Nagy P; Ostropolets A; Pistillo A; Phan TP; Pratt N; Reyes C; Richter L; Ross JS; Ruan E; Seager SL; Simon KR; Viernes B; Yang J; Yin C; You SC; Zhou JJ; Ryan PB; Schuemie MJ; Krumholz HM; Hripcsak G; Suchard MA
    J Am Coll Cardiol; 2024 Sep; 84(10):904-917. PubMed ID: 39197980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    Fu EL; Wexler DJ; Cromer SJ; Bykov K; Paik JM; Patorno E
    BMJ; 2024 Jun; 385():e078483. PubMed ID: 38925801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.
    Pai YW; Chen IC; Lin JF; Chen XH; Chen HH; Chang MH; Huang JA; Lin CH
    Diabetes Obes Metab; 2024 Nov; 26(11):5420-5430. PubMed ID: 39248211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Fu EL; Mastrorilli J; Bykov K; Wexler DJ; Cervone A; Lin KJ; Patorno E; Paik JM
    Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.
    Xie Y; Bowe B; Xian H; Loux T; McGill JB; Al-Aly Z
    Lancet Diabetes Endocrinol; 2023 Sep; 11(9):644-656. PubMed ID: 37499675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.